论文部分内容阅读
自1978年6月采用南大生物系与泰州生物化学制药厂提取的猪胸腺素组分5(以下简称PTHF_5)应用于临床,至1980年5月治疗自身免疫性疾病153例,各型肝炎120例,原发性与继发性细胞免疫功能低下等疾病201例,共计474例。病例材料由参加此项工作的20个单位提供(附录)。所应用的PTHF_5相当于小牛胸腺素组分5,系热稳定可溶性产物,分子量9,000～68,000,含主要蛋白质8～9种,不含糖类和核苷酸〈1〉。初步结果显示PTHF_5治疗系统性红斑狼疮(SLE)类风湿性关节炎(RA),重症肝炎,慢性肝炎以及麻风等疾病有一定疗效,现将此474例的初步结果简要介绍。
Since June 1978 using the Department of Biology and Taizhou Taizhou biochemical pharmaceutical pharmaceutical factory extraction of porcine thymosin component 5 (hereinafter referred to as PTHF_5) used in clinical treatment of autoimmune diseases in May 1980 153 cases, 120 cases of various types of hepatitis , Primary and secondary cellular immune dysfunction 201 cases, a total of 474 cases. Case material was provided by 20 units participating in the work (appendix). The applied PTHF_5 is equivalent to calf thymosin component 5, which is a thermostable soluble product with a molecular weight of 9,000 to 68,000, containing 8 to 9 major proteins, free of sugars and nucleotides <1>. The preliminary results show that PTHF_5 has some curative effect on the treatment of systemic lupus erythematosus (SLE) rheumatoid arthritis (RA), severe hepatitis, chronic hepatitis and leprosy. The preliminary results of 474 cases are briefly introduced.